Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated prices for Ozempic, Wegovy, and Rybelsus will be. In Medicare's negotiations ...

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the ...

Among the 10 drugs listed, Medicare Part D spent the most on Ozempic, Rybelsus and Wegovy, at $14.43 billion, according to a CMS fact sheet on Friday. Nearly 2.3 million enrollees used those drugs ...

In one of its last actions, the Biden administration released the next 15 drugs selected for Medicare negotiation and the blockbuster diabetes drug Ozempic will be among those bargained for this year.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

The move could mean savings for consumers. Weight loss drugs Ozempic and Wegovy have been added to the list of medications Medicare will be able to negotiate directly with drug manufacturers ...